首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD40LG |
| Uniprot No | P29965 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 113-261aa |
| 氨基酸序列 | MQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLT VKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTH SSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD40LG重组蛋白的参考文献示例(内容为模拟，实际文献需通过学术数据库查询)：
---
1. **标题**：*Recombinant CD40 ligand promotes B cell proliferation and immunoglobulin secretion in vitro*
**作者**：Armitage, R.J. et al.
**摘要**：研究利用重组CD40L蛋白在体外激活B细胞，证实其通过CD40信号通路促进B细胞增殖和抗体分泌，为免疫调节机制提供依据。
2. **标题**：*Therapeutic potential of recombinant CD40L in cancer immunotherapy*
**作者**：Vonderheide, R.H. et al.
**摘要**：探讨重组CD40L蛋白在肿瘤模型中的作用，显示其通过激活抗原呈递细胞增强抗肿瘤免疫反应，提示其作为癌症治疗药物的潜力。
3. **标题**：*Structural characterization of human CD40 ligand and its binding mechanism*
**作者**：Karpusas, M. et al.
**摘要**：通过X射线晶体学解析重组CD40L的三维结构，揭示其与CD40受体相互作用的关键位点，为靶向药物设计提供结构基础。
4. **标题**：*Recombinant CD40LG enhances vaccine efficacy in primate models*
**作者**：Barr, T.A. et al.
**摘要**：在非人灵长类动物模型中，重组CD40L蛋白作为疫苗佐剂显著增强抗原特异性抗体和T细胞应答，验证其临床应用可行性。
---
**提示**：以上为模拟示例，真实文献建议通过PubMed、Google Scholar等平台以关键词“recombinant CD40LG/CD40 ligand”检索。
CD40 ligand (CD40LG), also known as CD154. is a type II transmembrane protein belonging to the tumor necrosis factor (TNF) superfamily. It is primarily expressed on activated T cells and interacts with CD40. a receptor found on antigen-presenting cells (APCs) such as B cells, dendritic cells, and macrophages. This interaction is critical for adaptive immune responses, including B-cell activation, antibody class switching, germinal center formation, and T-cell-dependent immune regulation. Dysregulation of the CD40-CD40LG axis is linked to autoimmune diseases, immunodeficiency, and cancer.
Recombinant CD40LG is engineered through genetic modification, typically produced in mammalian expression systems (e.g., CHO or HEK293 cells) or *E. coli* to ensure proper folding and post-translational modifications. The recombinant protein often exists in soluble trimeric forms or fused with Fc tags to enhance stability and mimic its natural membrane-bound structure. Purification techniques like affinity chromatography ensure high purity and biological activity.
In research, recombinant CD40LG is used to study immune cell crosstalk, signal transduction pathways (e.g., NF-κB and MAPK), and mechanisms of immune tolerance. Therapeutically, it has potential in cancer immunotherapy to activate APCs and boost antitumor responses, as well as in vaccine adjuvants to improve antigen presentation. However, its clinical application requires caution due to risks of cytokine storms or autoimmunity from excessive CD40 activation.
Recent studies explore engineered variants of recombinant CD40LG with tuned binding affinity or delivery systems (e.g., nanoparticles) to improve targeting and reduce off-target effects. Its role in infectious disease models, particularly in enhancing pathogen-specific immunity, further underscores its versatility as a research and therapeutic tool.
×
